Karolinska Development portfolio company OssDsign will change CEO during second half of 2025

Group 1 - Karolinska Development's portfolio company OssDsign is undergoing a leadership change to enhance its focus on the US market [1][2] - OssDsign has transitioned to a pure-play orthobiologics company since launching OssDsign Catalyst in the US in August 2021, experiencing high double-digit growth [2] - Current CEO Morten Henneveld will ensure a smooth transition to new leadership and will leave his position by year-end or upon the appointment of a new CEO [3] Group 2 - Karolinska Development holds a 3% ownership stake in OssDsign [3] - The company focuses on identifying and investing in breakthrough medical innovations in the Nordic region, aiming to create and grow companies that develop these innovations into commercial products [4][5] - Karolinska Development has a portfolio of eleven companies targeting innovative treatments for serious diseases, supported by experienced management teams and a strong global network [6]